ARQT Latest Press Releases

-- November 6, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- November 5, 2026 --

Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis Globe Newswire 8:00 AM

-- November 4, 2026 --

Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:00 PM

-- October 28, 2026 --

Arcutis Appoints Rob Scott, MD to Board of Directors Globe Newswire 9:00 AM

-- October 27, 2026 --

Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference Globe Newswire 4:00 PM

-- October 21, 2026 --

Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026 Globe Newswire 4:00 PM

-- October 9, 2026 --

Arcutis Presents ZORYVE (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical Globe Newswire 8:00 AM

-- October 6, 2026 --

Arcutis' ZORYVE (roflumilast) Wins 2026 Marie Claire Beauty Award Globe Newswire 8:19 AM

-- October 2, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- September 29, 2026 --

Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options Globe Newswire 9:15 AM

-- September 4, 2026 --

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 PRNewswire 7:16 PM

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- September 2, 2026 --

Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference Globe Newswire 4:00 PM

-- August 20, 2026 --

PrZORYVE Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis PRNewswire 1:25 PM

-- August 7, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- August 5, 2026 --

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:00 PM

-- July 16, 2026 --

Arcutis Expands Board of Directors with Appointment of Chris Peetz Globe Newswire 9:00 AM

-- July 15, 2026 --

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Globe Newswire 4:00 PM

Attovia Therapeutics Appoints John W. Smither to Board of Directors Globe Newswire 8:30 AM

-- July 8, 2026 --

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months Globe Newswire 8:00 AM

-- July 2, 2026 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- June 30, 2026 --

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE (roflumilast) Indications Globe Newswire 9:15 AM

-- June 29, 2026 --

FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 Globe Newswire 7:06 PM

Market Data Delayed 15 Minutes